TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03509103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Partograph
Description: The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Partograph
Description: The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely.
Study: NCT01561274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 ml bupivacaine
Description: 2 ml bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 ml bupivicaine.
Description: 1.5 ml bupivicaine.
Study: NCT04094844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wearable activity sensor
Description: Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable activity sensor
Description: Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Roadmap 2.0 information system
Description: Caregivers and patients download the Roadmap 2.0 app on their mobile phones or tablets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey administration
Description: Caregivers and patients will be asked to respond to survey questions at 3 timepoints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey administration
Description: Caregivers and patients will be asked to respond to survey questions at 3 timepoints.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Roadmap 2.0 information system with Positive Activities
Description: Caregivers and patients download the Roadmap 2.0 app on their mobile phones. Caregivers and patients will be instructed on how to operate Roadmap 1.0 on an iPad (inpatient only) and Roadmap 2.0 on a mobile phone (inpatient and outpatient). Caregivers download the Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay.
Study: NCT04044768

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: afamitresgene autoleucel (previously ADP-A2M4)
Description: Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
Study: NCT04338061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.
Study: NCT04328805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Arginine tablets
Description: oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization
Description: Manual therapy maneuver performed in the upper limb
Study: NCT03256942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etermis 4®
Description: Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
Study: NCT02019290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral doses will be given on Days 1 and 15, after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin
Description: An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
Study: NCT02954757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Description: High intensity focused ultrasound
Study: NCT01767428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 500 mg immediate release paracetamol formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 500 mg immediate release paracetamol formulations
Study: NCT03664908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).
Description: biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).
Description: biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).
Description: biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
Study: NCT01888263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study: NCT01282606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-6603
Description: SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-6603
Description: SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-6603
Description: SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
Study: NCT05805657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Delayed Treatment
Description: Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
Study: NCT00628888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Adolescents (UP-A)
Description: All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Adolescents (UP-A)
Description: All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
Study: NCT00519142

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for mitiglinide
Description: three times a day with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitiglinide
Description: three times a day with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitiglinide
Description: two times a day with meals
Study: NCT03097393

Intervention type: DIAGNOSTIC_TEST
Intervention: measure Serum procalcitonin level
Description: measuring procalcitonin level

Intervention type: DIAGNOSTIC_TEST
Intervention: measure Serum procalcitonin level
Description: measuring procalcitonin level
Study: NCT00056160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
Study: NCT02268422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: 7 day patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 7 day patch
Study: NCT02376348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A targeted demand creation Activities
Description: Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
Study: NCT04175548

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT01302496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TriMix-DC and ipilimumab
Description: Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
Study: NCT00983710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC-PEP - Prostate Cancer Patient Education Program
Description: Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Booklet on coping with localized prostate cancer
Study: NCT02898909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nuclear lens fragmentation in 8 pieces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nuclear lens fragmentation in 16 pieces
Study: NCT04271826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic appendectomy
Description: cases with normal CT underwent laparoscopic appendectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic appendectomy
Description: cases with normal CT underwent laparoscopic appendectomy
Study: NCT02731157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rejuvesol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
Study: NCT04392271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: Administered orally.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]LSN3316612
Description: Administered intravenously (IV).
Study: NCT01096420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses.
Study: NCT03213886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcifediol (Vitamin D)
Description: After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~1. Will follow the usual hip fracture rehabilitation pathway.~2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol (Vitamin D)
Description: After surgical treatment, participants with vitamin D deficiency (25OHD \< 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~1. Will follow the usual hip fracture rehabilitation pathway.~2. 25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)
Study: NCT03397862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Donepezil patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle TDS
Description: Placebo patch
Study: NCT05149118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotide (PDRN)
Description: A total 1mL of PDRN was injected along the suture line at distance of 1cm in one day and two days after the surgery.
Study: NCT01709760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 15-25 mg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 15-25 mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENIA11
Description: ENIA11 25 mg, sc twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, sc twice weekly
Study: NCT04578158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard COVID-19 care
Description: Patients will receive standard covid-19 care as per the hospital/physician guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard COVID-19 care
Description: Patients will receive standard covid-19 care as per the hospital/physician guidelines

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin Phytosome
Description: Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
Study: NCT03538587

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Mindfulness Intervention
Description: The 8-week EMI will consist of one initial in-person session with the participant and parent, a series of at home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline.
Study: NCT02020707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01643707

Intervention type: BEHAVIORAL
Intervention: Evidence based guidelines and tools
Description: Education, guidelines, tools
Study: NCT03956264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalinox
Description: Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
Study: NCT05488613

Intervention type: DRUG
Intervention: Midostaurin
Description: Midostaurin was administered in two different dosing options. Either as 2x25mg daily or 2x50mg daily.
Study: NCT00714103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-Chloro-Adenosine
Description: 45 mg/m\^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
Study: NCT02844803

Intervention type: DRUG
Group type: OTHER
Intervention: Combination of Metformin + S. Baicalensis
Description: the combination therapy for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Combination of Metformin + S. Baicalensis
Description: the combination therapy for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Combination of Metformin + Placebo
Description: the metformin single therapy for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Combination of Metformin + Placebo
Description: the metformin single therapy for 8 weeks
Study: NCT01889836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 'MenCC-Bio'
Description: The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MENJUGATE
Description: The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.